Coprimary Objectives:~To evaluate the safety of PXVX0317 in healthy adult and adolescent participants 12 to <65 years of age.~To compare the anti-CHIKV serum neutralizing antibody (SNA) response to PXVX0317 and placebo at Day 22, as measured by geometric mean titer (GMT) and clinically relevant difference in seroresponse rate.~To demonstrate the consistency of the anti-CHIKV SNA response across three lots of PXVX0317 at Day 22.~Secondary Objectives:~To compare the anti-CHIKV SNA response to PXVX0317 and placebo at Day 15, Day 183, and Day 8.~To compare the anti-CHIKV SNA response to PXVX0317 and placebo in participants 12 to <18 years of age, participants 18 to <46 years of age, and participants 46 to <65 years of age.
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 in healthy adult and adolescent subjects.